Skip to main content
Equibles
GALT logo

GALT · Galectin Therapeutics Inc · Metrics

Track GALT — free

Use GALT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GALT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.19 -0.19 (-5.62%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months from the issuance date of these financial statements.”
View the 10-Q filed Aug 14, 2026
Market Cap
$321.71M
Shares
100.85M
Volume · Oct 23 195.22K Avg daily vol (3M) 303.16K

GALT metrics

61 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$3.19
Market cap
$321.71M

Price action

20 metrics
Price change (1W)
-11.9%
Price change (30D)
-18.2%
Price change (3M)
-8.1%
Price change (6M)
+36.9%
Price change (YTD)
-23.3%
Price change (1Y)
-37.8%
Trailing year
Price change (5Y)
-2.7%
52-week high
$6.51
52-week low
$2.08
Change from 52-week high
-51.0%
Change from 52-week low
+53.4%
Annualized volatility
91.1%
Annualized volatility (3M)
66.3%
Beta
0.7
RSI (14D)
32.4
Price vs SMA 50
-16.7%
Price vs SMA 200
-0.4%
Avg volume (3M)
303,159
Relative volume
0.6
Average dollar volume
$1.11M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
100.85M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-8.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-08-14

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$15.62M
Net income (TTM)
−$27.84M
Trailing 12 months
Diluted EPS (TTM)
$-0.43
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-0.24
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-0.43
Operating cash flow per diluted share (TTM)
$-0.24
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.14
Stock compensation per diluted share (TTM)
$0.04
Book value per share
$-1.96

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+3.8%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-187.8%
Debt / equity
—
Current ratio
0.1
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.1
Interest coverage
-2.0
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$13.27M
Latest balance sheet
Cash & equivalents
$13.27M
Total assets
$14.83M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$15.89M
Capital expenditures (TTM)
—
R&D (TTM)
$8.91M
SG&A (TTM)
—
Stock compensation (TTM)
$2.34M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
101
13F filer change QoQ
0
Institutional ownership
16.9%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
3.3%
Private-fund adviser ownership
3.1%
Active holders' share change QoQ
-20.3%
Holder tenure
12.1
Price vs estimated holder cost
+60.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
4.6%

Short interest

3 metrics
Short interest
9.1%
Latest settlement · 33.7 days to cover
Days to cover
33.7d
Short-squeeze score
65 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1133416 CUSIP 363225202 13F (30d) 15 filings 15 filers Visit website Investor relations